Scientific insights into brain fog during the menopausal transition

Clinicians and researchers engaged in the field of menopausal health understand that there are myriad physiological and psychological effects associated with the menopausal transition, including changes in cognitive function [1]. Longitudinal cohort studies suggest a ‘window of vulnerability’ for cognitive difficulties [2,3], particularly memory, beginning in the early menopause transition and apparently ending, at least for most women, in the postmenopause. Changes in sex steroid hormones, particularly 17b-estradiol, which exerts potent effects on the brain, play a key role in memory performance at midlife [4] as do vasomotor symptoms, sleep disturbance, and mood/anxiety [5]. Some studies suggest that longer lifetime exposure to endogenous 17bestradiol may be related to better cognitive processes in older women [6]. There are critical gaps in the knowledge of the neurobiological mechanisms contributing to those declines, the persistence of those declines, the extent to which hormonal changes and menopause symptoms contribute to cognitive declines, potential interventions that might be effective in ameliorating cognitive difficulties, and the long-term clinical significance of midlife cognitive changes. This themed edition of Climacteric focuses on menopause and cognition from a clinical translational perspective and addresses some of these gaps by drawing on both clinical and basic science. Four of the articles in this special edition address clinical presentation and protective/risk factors. Menopause practitioners can draw on a systematic review of 19 studies by Reuben and colleagues [7] to normalize and validate cognitive complaints in their patients. The authors found that cognitive complaints not only increased across the menopause transition, but were also associated with poorer performance on tests of attention, verbal and working memory. Focusing on cognitive test performance, Weber and colleagues [8] analyzed data from the Rochester Investigation of Cognition and Memory (RICAM) to examine the heterogeneity in cognitive changes in the perimenopause. They identified four distinct cognitive profiles, each characterized by different patterns of relative strengths and weaknesses in cognition over the perimenopause. Among 85 women evaluated over 400 bi-annual visits, about 20% of observations fit into a cognitively vulnerable profile characterized by weaknesses in verbal learning and memory. The factors associated with that profile were sleep disturbances and, interestingly, less hormonal variability. The good news for patients is that the remaining 80% of observations were in the other three cognitive profiles, which were distinct in terms of strengths and weaknesses but which fell under the normal range of cognitive performance. Lastly, among Thai women with a history of surgical menopause, Orprayoona and colleagues [9] demonstrate a high prevalence of frontal lobe dysfunction, while Chaikittisilpa and colleagues [10] reported a risk of mild cognitive impairment (MCI). These articles contribute to a better understanding of the types of cognitive changes experienced by women. Two papers consider mechanisms of action of estrogens in the brain. Baumgartner and Daniels [11] make a compelling case for the importance of estrogen receptor alpha (ERa) in female brain aging, even in the absence of endogenous or exogenous hormones. Prakapenka and Korol [12] present evidence that estrogens do not uniformly benefit cognition, but rather enhance or impair cognition in a task-dependent manner depending on the metabolic status of the brain areas subserving those tasks. For example, estrogens can enhance hippocampal-dependent memory by increasing glucose in the hippocampus but impair cognitive tasks dependent on the striatum by decreasing levels of lactate and ketones. Effects of menopausal hormone therapy (MHT) on cognition and brain function are complex, with guidelines from the International Menopause Society [13] noting that there is insufficient evidence to recommend its use for the treatment or prevention of cognitive dysfunction. A review by Kim and Brinton [14] makes the case for a personalized treatment approach that focuses on symptomatic women, and considers the duration and type of MHT, as well as genetic risk factors. Li and Dreher [15] review clinical neuroimaging studies showing beneficial effects of MHT on the structure and function of the prefrontal cortex in postmenopausal women. Hugenschmidt and colleagues [16] review evidence, including data from the Women’s Health Initiative, suggesting that type 2 diabetes mellitus modifies the effects of MHT on brain function in older women, conferring reliable negative effects and suggesting a need for a personalized medicine approach that limits use of MHT in women with that condition. Drawing from both clinical and basic science studies, they make a compelling case that the combination of hormone